Premier Alternatives

Kartos Therapeutics

Redwood City, CA · Founded 2018 · Privately Held (backing)

Operator of a biopharmaceutical company intended to offer investigational inhibitors for cancer treatment. Kartos Therapeutics is based in Redwood City, CA and was founded in 2018. It is valued at about $650 million as of Oct 2026, set by institutional fund marks. It has raised $265 million.

PMV mark · valuation
$650.0M
Oct 2026
Priced at
—
Total raised
$265.0M
Last round
—

Kartos Therapeutics key facts

as of Oct 2026
  • Operator of a biopharmaceutical company intended to offer investigational inhibitors for cancer treatment.
  • Kartos Therapeutics is valued at approximately $650.0M as of Oct 2026, per PrivateMarketView’s mark.
  • It has raised $265.0M; the latest was Later Stage VC in Feb 2025.
  • Notable investors include OrbiMed, SR One Capital Management, Amgen, Quogue Capital.
  • 1 institutional filer reports fund marks on Kartos Therapeutics across 11 filings.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$650.0M

Reported valuation; nothing comparable since.

set by institutional fund marksas of Oct 2026question about this number?
Free account
More of Kartos Therapeutics with a free account
  • ·Watch Kartos Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Institutional fund marks on Kartos Therapeutics

1 filers · latest Jul 2026

1 SEC-registered fund reported 11 fair-value marks on Kartos Therapeutics between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.

Unlock 11 fund marks

Membership and data by Private Market View

Every name the funds mark, next to where it trades →

Kartos Therapeutics funding rounds

No rounds on record

No funding rounds for Kartos Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Kartos Therapeutics valuation

Kartos Therapeutics is valued at approximately $650 million as of Oct 2026. The figure is set by institutional fund marks.

Recent activity

In the last 90 days, Kartos Therapeutics's record added 5 institutional fund marks (latest period Jul 2026).

Institutional holders and vehicles

1 SEC-registered fund reported 11 fair-value marks on Kartos Therapeutics between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

Kartos Therapeutics investors

4 investors are on record for Kartos Therapeutics, including OrbiMed, SR One Capital Management, Amgen and Quogue Capital.

About Kartos Therapeutics

Operator of a biopharmaceutical company intended to offer investigational inhibitors for cancer treatment. The company specializes in the development of novel, targeted therapeutics and provides a new treatment option for patients across selected solid tumors and hematological malignancies, enabling cancer patients to improve their lives.

Sector
Healthcare
HQ
Redwood City, CA, United States
Founded
2018
Employees
87
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.